Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Fatigue management in patients with IBD: a randomised controlled trial

View through CrossRef
Objective To assess the effectiveness of solution-focused therapy (SFT) on fatigue and quality of life (QoL) in patients with fatigued inflammatory bowel disease (IBD). Design Randomised controlled trial in two Dutch hospitals. Patients with IBD with quiescent IBD and with a Checklist Individual Strength—Fatigue (CIS—fatigue) score of ≥35 were enrolled. Patients were 1:1 randomised to receive SFT or care as usual (CAU) for 3 months. Patients were followed for a further 6 months after the SFT. Primary endpoint was defined as changes in fatigue and QoL during follow-up. Secondary endpoints included change in anxiety and depression, medication use, side effects to medication, disease activity, laboratory parameters (C-reactive protein, leucocytes and haemoglobin) and sleep quality. Results Ninety-eight patients were included, of whom 63% were women, mean age was 40.1 years. After the SFT course, 17 (39%) patients in the SFT group had a CIS-fatigue score below 35 compared with eight (18%) of patients in the CAU group (p=0.03). The SFT group also showed a greater reduction in fatigue across the first 6 months compared with the CAU group (CIS-fatigue: p=<0.001 and CIS-total: p=0.001). SFT was associated with a significant higher mean IBD questionnaire change at 3 months (p=0.020). At 9 months, no significant differences between the two groups were observed. Conclusions SFT has a significant beneficial effect on the severity of fatigue and QoL in patients with quiescent IBD. However, this effect diminished during follow-up.
Title: Fatigue management in patients with IBD: a randomised controlled trial
Description:
Objective To assess the effectiveness of solution-focused therapy (SFT) on fatigue and quality of life (QoL) in patients with fatigued inflammatory bowel disease (IBD).
Design Randomised controlled trial in two Dutch hospitals.
Patients with IBD with quiescent IBD and with a Checklist Individual Strength—Fatigue (CIS—fatigue) score of ≥35 were enrolled.
Patients were 1:1 randomised to receive SFT or care as usual (CAU) for 3 months.
Patients were followed for a further 6 months after the SFT.
Primary endpoint was defined as changes in fatigue and QoL during follow-up.
Secondary endpoints included change in anxiety and depression, medication use, side effects to medication, disease activity, laboratory parameters (C-reactive protein, leucocytes and haemoglobin) and sleep quality.
Results Ninety-eight patients were included, of whom 63% were women, mean age was 40.
1 years.
After the SFT course, 17 (39%) patients in the SFT group had a CIS-fatigue score below 35 compared with eight (18%) of patients in the CAU group (p=0.
03).
The SFT group also showed a greater reduction in fatigue across the first 6 months compared with the CAU group (CIS-fatigue: p=<0.
001 and CIS-total: p=0.
001).
SFT was associated with a significant higher mean IBD questionnaire change at 3 months (p=0.
020).
At 9 months, no significant differences between the two groups were observed.
Conclusions SFT has a significant beneficial effect on the severity of fatigue and QoL in patients with quiescent IBD.
However, this effect diminished during follow-up.

Related Results

Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Radical prostatectomy is the most commonly performed treatment option for localised prostate cancer. In the last decades the surgical technique has been improved and modified in or...
An Inflammatory Bowel Diseases Integrated Resources Portal (IBDIRP)
An Inflammatory Bowel Diseases Integrated Resources Portal (IBDIRP)
Abstract IBD, including ulcerative colitis and Crohn’s disease, is a chronic and debilitating gastrointestinal disorder that affects millions of people worldwide. Re...
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
Abstract Background Both inflammatory bowel disease (IBD) and ankylosing spondylitis (AS) are inflammatory diseases but there wa...
Serum neutrophil gelatinase associated lipocalin (NGAL) as a marker of activity in inflammatory bowel disease
Serum neutrophil gelatinase associated lipocalin (NGAL) as a marker of activity in inflammatory bowel disease
Abstract Inflammatory bowel disease (IBD) is a disease of activity and remission. Lipocalin 2 (LCN2), the coding gene for NGAL is one of the most over-expressed genes in th...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...

Back to Top